Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Operating Leases (2019 - 2021)

Cogent Biosciences has reported Operating Leases over the past 3 years, most recently at $1.4 million for Q3 2021.

  • Quarterly results put Operating Leases at $1.4 million for Q3 2021, down 61.04% from a year ago — trailing twelve months through Sep 2021 was $1.4 million (down 61.04% YoY), and the annual figure for FY2020 was $3.2 million, down 28.51%.
  • Operating Leases for Q3 2021 was $1.4 million at Cogent Biosciences, down from $2.0 million in the prior quarter.
  • Over the last five years, Operating Leases for COGT hit a ceiling of $5.6 million in Q1 2019 and a floor of $1.4 million in Q3 2021.
  • Median Operating Leases over the past 3 years was $3.7 million (2020), compared with a mean of $3.7 million.
  • Biggest five-year swings in Operating Leases: dropped 23.6% in 2020 and later plummeted 61.04% in 2021.
  • Cogent Biosciences' Operating Leases stood at $4.4 million in 2019, then fell by 28.51% to $3.2 million in 2020, then crashed by 54.42% to $1.4 million in 2021.
  • The last three reported values for Operating Leases were $1.4 million (Q3 2021), $2.0 million (Q2 2021), and $2.6 million (Q1 2021) per Business Quant data.